About Adapsyn
Adapsyn is a company based in Hamilton (United States) founded in 2016 by Nathan Magarvey. Adapsyn offers products and services including Genomics Platform, Metabolomics Platform, and Assay Biology Platform. Adapsyn operates in a competitive market with competitors including Evelo Biosciences, Kallyope, PathogenDX, Manus Bio and Newcells Biotech, among others.
- Headquarter Hamilton, United States
- Founders Nathan Magarvey
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adapsyn Bioscience Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Gates Foundation
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Adapsyn
Adapsyn offers a comprehensive portfolio of products and services, including Genomics Platform, Metabolomics Platform, and Assay Biology Platform.
Identifies microbial strains for novel chemistry and drug prediction.
Detects compounds from microbes for evaluation and isolation.
Generates chemical libraries for screening and biochemical assays.
People of Adapsyn
Unlock access to complete
Unlock access to complete
Board Team
4 people
Leadership Team
2 people
Software Development Team
2 people
Operations Team
1 people
Unlock access to complete
Funding Insights of Adapsyn
Investors in Adapsyn
Adapsyn has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Genesys Capital and Pfizer Venture Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life sciences companies are supported through venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital is focused on healthcare by Pfizer's investment arm.
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for Adapsyn
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adapsyn
Investment portfolio details for Adapsyn
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Adapsyn
Detailed financials for Adapsyn
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adapsyn Comparisons
Peer comparison for Adapsyn
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adapsyn
Adapsyn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, Kallyope, PathogenDX, Manus Bio and Newcells Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| Locked | Locked | Locked |
The gut-brain axis is explored for therapeutic and nutritional innovations.
|
|
| Locked | Locked | Locked |
Provider of DNA-based pathogen testing kits
|
|
| Locked | Locked | Locked |
Phytochemicals are developed using microbial fermentation processes.
|
|
| Locked | Locked | Locked |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| Locked | Locked | Locked |
Cell-based assays and 3D microtissues for drug screening are developed.
|
Detailed competitors of Adapsyn
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adapsyn
Complete news archive for Adapsyn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adapsyn
Adapsyn was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Adapsyn is headquartered in Hamilton, United States.
Adapsyn was founded in 2016 in Hamilton, United States. Computational tools are offered for bacterial metabolomic and genomic data analysis within the biotechnology sector. Proprietary machine learning is applied to microbial data to identify natural products encoded in genomes. Technology platforms such as PRISM, GARLIC, GRAPE, CLAMS, and ADAPSYN GRAPH are utilized for artificial intelligence in natural product drug discovery.
Adapsyn's top competitors include PathogenDX, Manus Bio and Newcells Biotech.
Adapsyn offers Genomics Platform, Metabolomics Platform, and Assay Biology Platform.
Adapsyn has 3 investors. Key investors include Gates Foundation, Genesys Capital, and Pfizer Venture Investments.